Acer therapeutics inc. (ACER)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating expenses:
Option Revenue

-

-

-

-

2,556

1,271

1,266

-

-

-

Research and development

13,851

12,452

8,725

5,308

10,039

12,118

9,181

6,318

3,340

2,584

General and administrative

16,046

9,261

5,223

1,391

4,258

3,833

3,670

2,508

2,406

2,216

Total operating expenses

29,897

21,713

13,948

6,699

-

-

-

-

-

-

Loss from operations

-29,897

-21,713

-13,948

-6,699

-12,093

-15,067

-11,923

-9,133

-5,966

-4,970

Other income, net:
Interest income (expense), net

-

-

-

-

5

13

-

-

-

-

Interest income

471

412

14

0

-

-

14

0

0

1

Loss on extinguishment of debt

-

-

-

-

-

-

-2,518

-

-

-

Gain on derivative instruments

-

-

-

-

-

-

-

552

-

-

Interest expense

-

-

-

-

-

-

2,267

350

3

500

Interest and other expense

-

-

-245

0

-

-

-

-

-

-

Foreign currency transaction (loss) gain

8

20

-16

0

-

-

-

-

-

-

Total other income, net

479

433

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

351

387

335

303

210

168

Impairment loss

-

-

-

-

0

-

-

-

-

-

Loss on disposal of asset

-

-

-

-

-1

0

-2

-3

-9

-0

Total other income, net

-

-

-246

0

68

2

37

-

-

-

Net loss

-29,417

-21,280

-14,194

-6,699

-12,019

-15,052

-16,656

-8,930

-5,968

-5,469

Net loss per share - basic and diluted

-2.91

-2.49

-3.84

-2.73

-2.05

-4.33

-1.25

-1.54

-1.06

-0.32

Weighted average common shares outstanding - basic and diluted

10,092

8,555

3,694

2,450

5,854

3,477

13,332

5,785

5,633

-

Weighted average shares outstanding

-

-

-

-

-

-

-

-

-

17,071